Early progression of diabetic nephropathy correlates with methylglyoxal-derived advanced glycation end products

Diabetes Care

Volumn 36, Issue 10, 2013, Pages 3234-3239

  Beisswenger, Paul J ^a   Howell, Scott K ^a   Russell, Gregory B ^b   Miller, Michael E ^b   Rich, Stephen S ^c   Mauer, Michael ^d  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b WAKE FOREST UNIVERSITY   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINOADIPIC ACID; 3 DEOXYGLUCOSONE; 6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT; BIOLOGICAL MARKER; CARBOXYETHYLLYSINE; HEMOGLOBIN A1C; METHIONINE SULFOXIDE; METHYLGLYOXAL; METHYLGLYOXAL HYDROIMIDAZOLONE; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; DIABETIC NEPHROPATHY; DISEASE COURSE; FEMALE; GLOMERULUS BASEMENT MEMBRANE; HUMAN; HUMAN TISSUE; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY BIOPSY; KIDNEY HYPERTROPHY; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE;

ADOLESCENT; ADULT; CHILD; DIABETIC NEPHROPATHIES; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; IMIDAZOLES; MALE; PYRUVALDEHYDE; YOUNG ADULT;

EID: 84888108332     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-2689     Document Type: Article

References (39)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329: 977-986
2. Turner RC, Cull CA, Frighi V, Holman RR; UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999;281:2005-2012
3. Caramori ML, Fioretto P, Mauer M. The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient? Diabetes 2000;49:1399-1408
4. Drummond K, Mauer M; International Diabetic Nephropathy Study Group. The early natural history of nephropathy in type 1 diabetes: II. Early renal structural changes in type 1 diabetes. Diabetes 2002; 51:1580-1587
5. Mogensen CE, Christensen CK. Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med 1984;311:89-93
6. Perkins BA, Krolewski AS. Early nephropathy in type 1 diabetes: the importance of early renal function decline. Curr Opin Nephrol Hypertens 2009;18:233-240
7. Fioretto P, SteffesMW, Barbosa J, Rich SS, Miller ME, Mauer M. Is diabetic nephropathy inherited? Studies of glomerular structure in type 1 diabetic sibling pairs. Diabetes 1999;48:865-869
8. Dluhy RG, McMahon GT. Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med 2008;358: 2630-2633
9. Cefalu WT. Glycemic targets and cardiovascular disease. N Engl J Med 2008;358: 2633-2635
10. Monnier L, Colette C. Contributions of fasting and postprandial glucose to hemoglobin A1c. Endocr Pract 2006;12 (Suppl. 1):42-46
11. Beisswenger PJ, Howell SK, O'Dell RM, Wood ME, Touchette AD, Szwergold BS. alpha-Dicarbonyls increase in the postprandial period and reflect the degree of hyperglycemia. Diabetes Care 2001;24: 726-732
12. Ceriello A, Hanefeld M, Leiter L, et al. Postprandial glucose regulation and diabetic complications. Arch Intern Med 2004;164:2090-2095
13. Rohlfing CL, Wiedmeyer HM, Little RR, England JD, Tennill A, Goldstein DE. Defining the relationship between plasma glucose and HbA(1c): analysis of glucose profiles and HbA(1c) in the Diabetes Control and Complications Trial. Diabetes Care 2002;25:275-278
14. Clustering of long-term complications in families with diabetes in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. Diabetes 1997;46:1829-1839
15. Seaquist ER, Goetz FC, Rich S, Barbosa J. Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med 1989;320:1161-1165
16. Lachin JM, Genuth S, Nathan DM, Zinman B, Rutledge BN; DCCT/EDIC Research Group. Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications triald revisited. Diabetes 2008;57:995-1001
17. Krolewski AS,Warram JH, Rand LI, Kahn CR. Epidemiologic approach to the etiology of type I diabetes mellitus and its complications. N Engl J Med 1987;317:1390-1398
18. Andersen AR, Christiansen JS, Andersen JK, Kreiner S, Deckert T. Diabetic nephropathy in Type 1 (insulin-dependent) diabetes: an epidemiological study. Diabetologia 1983;25:496-501
19. Prager TC, Wilson DJ, Avery GD, et al. Vitreous fluorophotometry: identification of sources of variability. Invest Ophthalmol Vis Sci 1981;21:854-864
20. Pettitt DJ, Saad MF, Bennett PH, Nelson RG, Knowler WC. Familial predisposition to renal disease in two generations of Pima Indianswith type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1990;33: 438-443
21. Caramori ML, Kim Y, Huang C, et al. Cellular basis of diabetic nephropathy: 1. Study design and renal structural-functional relationships in patients with long-standing type 1 diabetes [published correction appears in Diabetes 2002;51:1294]. Diabetes 2002;51:506-513
22. Beisswenger PJ, Drummond KS, Nelson RG, Howell SK, Szwergold BS, Mauer M. Susceptibility to diabetic nephropathy is related to dicarbonyl and oxidative stress. Diabetes 2005;54:3274-3281
23. Lu J, Randell E, Han Y, Adeli K, Krahn J, Meng QH. Increased plasma methylglyoxal level, inflammation, and vascular endothelial dysfunction in diabetic nephropathy. Clin Biochem 2011;44:307-311
24. Beisswenger P, Howell S, Szwergold B, et al. Progression of diabetic nephropathy is predicted by increased oxidative stress and decreased deglycation (Abstract). Diabetologia 2008;51(Suppl. 1):S24
25. Ahmed N, Babaei-Jadidi R, Howell SK, Beisswenger PJ, Thornalley PJ. Degradation products of proteins damaged by glycation, oxidation and nitration in clinical type 1 diabetes.Diabetologia 2005;48:1590-1603
26. Ahmed N, Babaei-Jadidi R, Howell SK, Thornalley PJ, Beisswenger PJ. Glycated and oxidized protein degradation products are indicators of fasting and postprandial hyperglycemia in diabetes. Diabetes Care 2005;28:2465-2471
27. Drexel H, Klocker H, Patsch JR, Breier C, Braunsteiner H. Measurement of glycated protein by a rapid and specific method for absolute quantification of lysine-bound glucose. Clin Chem 1987;33:1656-1659
28. Drummond KN, Kramer MS, Suissa S, et al.; International Diabetic Nephropathy Study Group. Effects of duration and age at onset of type 1 diabetes on preclinical manifestations of nephropathy. Diabetes 2003;52:1818-1824
29. Caramori M, Parks A, Mauer M. Renal lesions and diabetic nephropathy risk in type 1 diabetes. J Am Soc Nephrol. In press
30. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005;54:1615-1625
31. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 1999;48:1-9
32. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813-820
33. Kalea AZ, Schmidt AM, Hudson BI. RAGE: a novel biological and genetic marker for vascular disease. Clin Sci (Lond) 2009;116: 621-637
34. Monnier VM, Sell DR, Genuth S. Glycation products as markers and predictors of the progression of diabetic complications. Ann N Y Acad Sci 2005;1043:567-581
35. Genuth S, Sun W, Cleary P, et al.; DCCT Skin Collagen Ancillary Study Group. Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. Diabetes 2005;54:3103-3111
36. Perkins BA, Rabbani N, Weston A, et al. Serum levels of advanced glycation endproducts and other markers of protein damage in early diabetic nephropathy in type 1 diabetes. PLoS One 2012;7:e35655
37. Steinke JM, Sinaiko AR, Kramer MS, Suissa S, Chavers BM, Mauer M; International Diabetic Nephopathy Study Group. The early natural history of nephropathy in Type 1 Diabetes: III. Predictors of 5-year urinary albumin excretion rate patterns in initially normoalbuminuric patients. Diabetes 2005;54:2164-2171
38. Fioretto P, Steffes MW, Mauer M. Glomerular structure in nonproteinuric IDDM patients with various levels of albuminuria. Diabetes 1994;43:1358-1364
39. Giorgino F, Laviola L, Cavallo Perin P, Solnica B, Fuller J, Chaturvedi N. Factors associated with progression to macroalbuminuria in microalbuminuric Type 1 diabetic patients: the EURODIAB Prospective Complications Study. Diabetologia 2004;47:1020-1028